Glioblastoma (GBM) is the most aggressive form of primary brain cancer, with a median survival of only 12–18 months despite surgery, radiation, and chemotherapy. It remains difficult to treat due to the blood–brain barrier, an immunosuppressive tumor environment, and genetic variability, which drive resistance and recurrence. GBM is often associated with epilepsy, further worsening patients’ quality of life. With tens of thousands of new cases globally each year, it represents a major unmet medical need.
Our approach uses monoclonal antibodies (mAbs) targeting connexins—key proteins involved in intercellular communication within tumors. Connexins are largely unexplored as therapeutic targets but play a central role in tumor growth, resistance, and potentially tumor-related epilepsy. By disrupting their function, mAbs may not only slow or stop tumor progression in glioblastoma and other brain cancers but also reduce or prevent the onset of associated epileptic activity, offering a new and more comprehensive therapeutic strategy where current treatments fall short.